Property Detail Full Name Body Protection Compound 157 Amino Acids 15 (pentadecapeptide) Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Molecular Weight ~1,419 g/mol Forms reviewed by FDA Free base and acetate salt FDA Status Not approved Active IND applications None (as of April 2026) Compounding status Under reclassification review (July 23-24, 2026) Is BPC-157 FDA Approved in 2026
Some providers split the dose into two smaller injections per day (morning and evening) for sustained signaling, though once daily is most common
MOTS-c promotes NRF2 activation, upregulating genes for glutathione synthesis, superoxide dismutase, and catalase [3]
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
